FDA has cleared Consano Bio's IND for C-1101, a platelet-derived biologic delivered via single epidural injection, enabling U.S. expansion of a Phase I trial targeting chronic sciatica. Consano Bio ...

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, describes how China’s recent export control updates may introduce new vulnerabilities for ...

David Hung, president, CEO, and founder of Nuvation Bio, discusses his leadership style, emphasizing the importance of hiring ...

Viral surveillance and predictive modeling are used to map mutational escape pathways and inform proactive antibody design against likely future variants rather than only current circulating strains.

Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...

Expanded scope adds a CNS program built on a PandaOmics-derived novel mechanism of action, aiming to improve translational efficiency from early discovery to clinical proof-of-concept. Financial ...

Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...

LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...

In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...